Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I)-Reference-Cited by-同舟云学术

Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I)

Published:2013-11-22 Issue:1 Volume:24 Page:33-40
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:Modern Rheumatology

Author:

Yamanaka Hisashi¹,Sugiyama Naonobu²,Inoue Eisuke¹,Taniguchi Atsuo¹,Momohara Shigeki¹

Affiliation:

1. Institute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan., , ,

2. Medical Affairs, Pfizer Japan Inc., Shinjuku Bunka Quint Bldg., 3-22-7 Yoyogi, Shibuya-ku, Tokyo 151-8589, Japan.

Publisher

Oxford University Press (OUP)

Subject

Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.3109/14397595.2013.854059

Reference9 articles.

1. Increase in age at onset of rheumatoid arthritis in Japan over a 30 year period

2. Changes in the incidence and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965-1996

3. The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease activity of rheumatoid arthritis and kidney function decline: a large prospective registry study;Annals of the Rheumatic Diseases;2024-08-21

2. Genetic testing and human leukocyte antigen in patients with hypertrophic cardiomyopathy and connective tissue diseases;Frontiers in Genetics;2024-08-06

3. Methotrexate, Tofacitinib, and Biologic Disease-Modifying Antirheumatic Drug Safety and Effectiveness Among Patients with Rheumatoid Arthritis in Japan: CorEvitas Registry Observational Study;Rheumatology and Therapy;2024-07-27

4. Safety of Tocilizumab on Rheumatoid Arthritis in Patients with Interstitial Lung Disease;Open Access Rheumatology: Research and Reviews;2024-06

5. Individual and population-level variability in HLA-DR associated immunogenicity risk of biologics used for the treatment of rheumatoid arthritis;Frontiers in Immunology;2024-05-15